



AF Ifw

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
Group Art Unit 1652

In re

Patent Application of

Rodney A. Welch, *et al.*

Application No. 10/002,309

Confirmation No.: 2988

Filed: October 26, 2001

Examiner: Tekchand Saidha

"E. COLI O157:H7 C1 ESTERASE
INHIBITOR BINDING PROTEIN AND
METHODS OF USE"

I, Leslie Lindsay Smith, hereby certify that this correspondence is being deposited with the US Postal Service as first class mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date of my signature.

Leslie Lindsay Smith
Signature

30 Aug. 2004
Date of Signature

OK to enter
Jc8
9/13/04

AMENDMENT AND RESPONSE UNDER 37 C.F.R. 1.116

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In the matter of the above-identified application, and in response to the Final Office Action mailed April 28, 2004, Applicants request entry of the amendments, reconsideration on the merits, withdrawal of the rejections, and allowance of the claims. A request for a one-month extension of time, extending the period for reply to Saturday, August 28, 2004 accompanies this response. Because the extended period for reply fell on a Saturday and the response is being filed Monday, August 30, 2004, the response is being timely filed within the extended period for reply.

Amendments to the claims are reflected in the listing of the claims, which begins on page 2.

Remarks begin on page 4 of this paper.

09/02/2004 HVB0651 00000055 10002309

01 FC:2231

55.00 00

10/002, 309

After final
OK to enter
Jk8
9/13/04

LISTING OF THE CLAIMS

What is claimed is:

1. (Currently amended) An isolated polypeptide comprising the amino acid sequence of amino acid residues 230-630 of SEQ ID NO:2, wherein the polypeptide comprises a StcE specific immunogen or has the ability to bind to and cleave C1 esterase inhibitor.
2. (Original) The polypeptide of claim 1, wherein the polypeptide comprises amino acid residues 85-734 of SEQ ID NO:2.
3. (Original) The polypeptide of claim 1, wherein the polypeptide comprises amino acid residues 24-886 of SEQ ID NO:2.
4. (Original) The polypeptide of claim 1, wherein the polypeptide has the ability to bind to and cleave C1 esterase inhibitor.
5. (Previously presented) An isolated polypeptide comprising an amino acid sequence having at least 95% amino acid identity to amino acid residues 24-886 of SEQ ID NO:2, the polypeptide comprising a sequence corresponding with and identical to amino acids 434-444 of SEQ ID NO:2, the polypeptide having the ability to bind to and cleave C1 esterase inhibitor.
- ✓ 6. (Currently amended) An isolated polypeptide, the amino acid sequence of which ^{consists of} ~~comprises~~ at least 17 consecutive amino acid residues of SEQ ID NO:2, wherein the polypeptide ^{consists of} ~~comprises~~ a StcE specific immunogen.
- ✓ 7. (Original) The polypeptide of claim 6, wherein the amino acid sequence ^{consists of} ~~comprises~~ at least 25 consecutive amino acid residues of SEQ ID NO:2.
- ✓ 8. (Original) The polypeptide of claim 6, wherein the amino acid sequence ^{consists of} ~~comprises~~ at least 40 consecutive amino acid residues of SEQ ID NO:2.
9. (Original) The polypeptide of claim 6, wherein the amino acid sequence comprises amino acid residues 430-446 of SEQ ID NO:2.
10. (Original) The polypeptide of claim 6, wherein the amino acid sequence comprises amino acid residues 421-446 of SEQ ID NO:2.

Examiner's
amendment
are
shown
for
claims
6-8
Jk8

11. (Original) The polypeptide of claim 6, wherein the amino acid sequence comprises amino acid residues 408-448 of SEQ ID NO:2.

12-21 (Canceled)